Ronald van Vollenhoven
Vollenhoven, Ronald van
Vollenhoven, Ronald F. van 1960-
VIAF ID: 271871907 (Personal)
Permalink: http://viaf.org/viaf/271871907
Preferred Forms
- 100 0 _ ‡a Ronald van Vollenhoven
- 100 1 _ ‡a Vollenhoven, Ronald F. van ‡d 1960-
-
- 100 1 _ ‡a Vollenhoven, Ronald van
-
-
4xx's: Alternate Name Forms (10)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Advances in the management of rheumatoid arthritis, 2009: | |
Clinical therapy research in the inflammatory diseases, 2015 : | |
Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response | |
Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial | |
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years | |
Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort | |
Lupus Science and Medicine: the Editors present highlights for the bedside and for the bench in the inaugural issue | |
Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus | |
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis | |
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab | |
Moving towards a molecular taxonomy of autoimmune rheumatic diseases. | |
Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study | |
Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples | |
Observational studies: a valuable source for data on the true value of RA therapies | |
Off-label use of rituximab for systemic lupus erythematosus in Europe | |
Patient preference assessment reveals disease aspects not covered by recommended outcomes in polymyositis and dermatomyositis | |
Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging stu | |
Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort | |
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial | |
Prevalence and comorbidity of relapsing polychondritis | |
The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients | |
Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria. | |
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations | |
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers. | |
Response to: 'MBDA: what is it good for?' by Yazici et al. | |
Rheumatoid Arthritis: Treatment [151-201]: 151. Should we be Looking More Carefully for Methotrexate Induced Liver Disease? | |
Rheumatologists, take heart! We may be doing something right | |
Rituximab and lupus--a promising pair? | |
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis | |
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration | |
Rituximab - shadow, illusion or light? | |
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis | |
Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids | |
The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving st | |
Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial | |
Skewed distribution of proinflammatory CD4+CD28null T cells in rheumatoid arthritis | |
Small molecular compounds in development for rheumatoid arthritis | |
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus | |
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. | |
Swedish registers to examine drug safety and clinical issues in RA. | |
Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue | |
Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis | |
Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. | |
Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. | |
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists | |
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial | |
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis | |
Treat-to-target in systemic lupus erythematosus: Where are we? | |
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force | |
Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense | |
Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. | |
Unresolved issues in biologic therapy for rheumatoid arthritis | |
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials | |
Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen | |
VH4-34 encoded antibody in systemic lupus erythematosus: effect of isotype | |
VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis |